Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:23:09 2024-03-28 pm EDT 5-day change 1st Jan Change
20.84 USD +0.34% Intraday chart for Denali Therapeutics Inc. -0.83% -2.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Denali Therapeutics Files Prospectus for Secondary Offering MT
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors CI
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study MT
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint DJ
Sanofi: failure of a phase 2 trial against ALS CF
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing MT
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium CI
Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium CI
Transcript : Denali Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 10:30 AM
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases CI
Citigroup Initiates Denali Therapeutics With Buy Rating, Price Target is $32 MT
Earnings Flash (DNLI) DENALI THERAPEUTICS Reports Q3 Revenue $1.3M MT
Denali Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Denali Therapeutics Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 11:30 AM
B. Riley Initiates Denali Therapeutics at Buy With $38 Price Target MT
Blood test for Parkinson's disease promising in early study RE
Denali Therapeutics Reports Positive Interim Data From Study of Enzyme Replacement Therapy DNL310 MT
Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 in MPS II (Hunter Syndrome) at SSIEM 2023 CI
Wedbush Lowers Denali Therapeutics' Price Target to $31 From $37 Following Pipeline Updates, Keeps Outperform Rating MT
Chart Denali Therapeutics Inc.
More charts
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
20.77 USD
Average target price
42.8 USD
Spread / Average Target
+106.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Denali Therapeutics Inc. - Nasdaq
  4. News Denali Therapeutics Inc.
  5. Denali Therapeutics Initiates Phase 1/2 Clinical Trial of DNL593 to Treat Frontotemporal Dementia-Granulin; Shares Rise Early